Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Anesthesia Pharm Exam 2 > ANS Phys & Pharm > Flashcards

ANS Phys & Pharm Flashcards

1
Q

ANS Reflexes - CNS:

Cushing’s Triad

A

1) Increased ICP
2) Bradycardia
3) Hypertension

Intracranial HTN leads to SNS mediated systemic HTN. Activation of the PSNS medullary centers via baroreflex slows HR (but not enough to reduct HTN!). This results in increased blood flow to brain & further increased ICP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ANS Reflexes - CNS:

Autonomic HYPERreflexia

A

1) Disruption of efferent impulses down the SC from T5 or higher.
2) Exaggerated SNS response to bowel, bladder, or surgical stimuli d/t receptor sensitivity 2/2 denervation
3) Loss of inhibitory impulses results in pure SNS response (HTN!)

Anesthesia impact: mgmt of quads/paras consists of spinal or GA with careful manipulation of BP due to alterations in ANS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ANS Reflexes - CNS:

Thermogenesis Reflex

A

1) Sweating controlled by cholinergic fibers (blocked by atropine or nerve blocks)
2) Shivering decreased in elderly, absent in newborns, blocked by NMDR’s
3) GA impair thermogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

All GA ________ thermogenesis reflexes.

A

All GA impair thermogenesis reflexes.

Sweating threshold is increased and vasoconstriction and shivering thresholds are markedly decreased. Can lead to hypothermia during surgery if heat loss thorugh radiation, convection, conduction, and evaporation are not minimized.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

ANS Reflexes - Cardiac:

Baroreceptor

A
  • stretch receptors in aorta and carotid arteries sense increased pressure
  • send signals via Hering Nerve & Vagus (CNX) to medulla
  • decreased HR, decreased BP, decreased contractility, decreased PVR
  • Phenylephrine (a1-agonist) increases BP and reflex decreases HR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ANS Reflexes - Cardiac:

Chemoreceptor

A
  • Instead of sensing BP (baroreflex), chemoreceptors sense increased arterial CO2 and decreased arterial pH.
  • HYPERcarbia increases minute ventilation.
  • Peripheral in carotid body respond to decreased PO2.
  • N. Hering and Vagus increase RR and TV which increases minute ventilation
  • may also see increased HR and CO.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

ANS Reflexes - Cardiac:

Bainbridge Reflex

A
  • increasd CVP activates stretch receptors in the atria
  • afferent impulses through vagus inhibit PSNS output resulting in tachycardia
  • seen during labor when contractions autotransfuse and increase CVP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ANS Reflexes - Cardiac:

Bezold-Jarisch

A

1. hypotension

2. bradycardia

3. coronary dilation

  • noxious stimuli (chemical or mechanical) sensed in cardiac ventricles
  • unmyelinated -fibers of vagus send signals to 1) enhance baroreflex, 2) inhibit sympathetic output and 3) decrease PVR to make it easier for heart to pump.
    • increased blood flow to the myocardium to decrease the work of the heart (cardioprotective)*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ANS Reflexes - Cardiac:

Oculocardiac (Five & Dime Reflex)

A
  • afferent impulses to pressure on the eye or pulling on eye muscle
  • efferent slowing of HR via Vagus N
  • muscarinic response can be blocked by atropine or glycopyrolate (so surgeon can proceed with procedure)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Five & Dime

A
  • Afferent through CN V
  • Efferent through CN X Vagus

= five and dime

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Anesthetic Interactions:

A2 agonists are _______ and reduce anesthetic needs.

A

A2 agonists are inhibitory and reduce anesthetic needs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Anesthetic Interactions:

Fentanyl _______ SNS tone and _______ vagal activation.

A

Fentanyl depresses SNS tone and promotes vagal activation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Anesthetic Interactions:

Des _____ the ANS and _____ the SNS (so we see HTN and tachycardia)

A

Des depresses the ANS and stimulates the SNS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Comorbid Implications:

Aging

A
  • HTN and orthostasis
  • temperature regulation
  • increased circulating NE (receptor downregulation and decreased responses to exogenous catecholamines)
  • decreased renin, decreased aldosterone, increased ANP = salt wasting!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Comorbid Implications:

DM

A
  • 20-40% IDDM have neuropathies (ANS)
  • labile BP, gastroparesis, altered thermoregulation, ?vagal dysfunction
  • increased aspiration risk, aggressive temp maintenance, increased CO
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Comorbid Implications:

Dysautonomia

A
  • Shy-Drager syndrome, Guillain Barre, Lambert-Eaton, Postural Orthostatic Hypotension, HR variability, BP lability

dysautonomia - umbrella term used to describe several different medical conditions that cause a malfunction of the Autonomic Nervous System.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Endogenous Catecholamines

A
  • EPi
  • NE
  • Dopamine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Epi

A
  • produced in adrenal medulla (80% Epi, 20% NE)
  • Adrenal standard secretion rates:
    0. 2 mcg/kg/min Epi
    0. 05 mcg/kg/min NE

- Exogenous Infusion Rate:

2-10mcg/kg/min (B1, B2)

>10mcg/kg/min (A1)

Anaphylaxis 0.2-0.5 mg sub-Q

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

NE

A
  • NE has >A1 and no B2 effects than Epi
  • 4-12 mcg/min (A1, B)

At Low Dose: B1 dominates & BP increases 2/2 increased CO

At High Dose: A1 dominates and BP increases, but HR and CO may decrease 2/2 baroreflex

  • beware effect on pulm A1 and possible pulm HTN and R HF
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Dopamine

A
  • precursor to Epi and NE
  • Exogenous dopamine does not cross BBB (L-dopa for parkinson’s)

Low Dose: 1-3 mcg/kg/min = D1 activation (coronary, renal, mesenteric vasodilation)

Moderate Dose: 3-10 mcg/kg/min = B1

High: >10 mcg/kg/min = A1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Metabolism of catecholamines

A
  • COMT is intracellular
  • MAO in nerve terminal mitochondria
  • Exogenous catecholamines may resist COMT and MAO metabolism
    • MAOIs will cause more of these to be available*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Exogenous Catecholamines:

Dopamine D1 Receptor Agonists - Fenoldopam

A
  • minimal D-2, a or b effects
  • 10x potency of dopamine
  • dosed 0.1-0.8 mcg/kg/min
  • 0.1-0.2 mcg/kg/min = renal vasodilation, increased renal blood flow and GFR, and Na+ excretion
  • improved outcome in CABG pts w less renal failure!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Exogenous Catecholamines:

a1 receptor agonists

A
  • increase BP and MVO2 supply
  • decrease hr
  • variable CO
  • this is good! increased BP and decreased HR = better perfusion to coronaries!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

phenylephrine

A
  • almost pure A agonist
  • > venoconstriction than arterial (increases venous return, maintains CO, HR decreases 2/2 baroreceptors)
  • NOT contraindicated in OB (but not necessarily better than ephedrine)
  • neosynephrine nasal spray
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

methoxamine

A

> arterial constriction than veno; longer acting; no longer in clinical use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

midodrine

A
  • oral A1 agonist used for dialysis induced hypotension
  • T1/2 3 hours
  • duration 4-6 hours
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Miller Figure 16-4

A
28
Q

Predominant Physiologic Effects of A1 and Dopamine (D) Receptor Activation

A
29
Q

A2 agonists

A
  • decrease CNS sympathetic output
  • decrease presynaptic NE release
  • sedation, hypnosis, sympatholysis, neuroprotection, diuresis, inhibition of insulin and HGH secretion
  • rapid delivery may increase P 2/2 postsynaptic a2b receptor mediated arterial and venoconstriction
30
Q

Beneficial anesthetic effects of A2 agonists (dex)

A
  • anxiolysis
  • sedation
  • decreased MAC
  • decreased opioid induced chest wall rigidity
  • decreased BP response to ETT, extubation and incision
  • decreased post-op shivering
31
Q

Dexmedetomidine

A
  • selective A2 agonist (1620:1 a2:a1 activity)
  • PACU pts on Dex require less morphine
  • decreased post op analgesics, b-blockers, antiemetics,diuretics and EPI for cabg pts

dosing:

Load 1 mcg/kg/hr over 10-20 min

Infusion 0.2-0.7 mcg/kg/hr

beware: hypotension and bradycardia

32
Q

clonidine

A

220: 1 a2:a1 activity
- oral dosing q8 hours, do NOT hold 2/2 rebound HTN
- can be used in epidural but w inconsistent results

33
Q

Isoproterenol

A
  • isopropyl derivative of EPI
  • nonselective activity at B1 and B2 (works at both receptors!)
  • high dose = tachycardia and hypotension (BAD!)
  • may be used as “chemical” pacemaker
34
Q

Dobutamine

A
  • derivative of dopamine
  • B1 agonist and A1 antagonist; minimal B2 effects
  • increased CO, decreased LV filling pressure
  • variable HR and SVR until dose >10-20 mcg/kg/min
  • dobutamine stress tests
35
Q

B1 and B2 visual

A
36
Q

B2 agonists (lungs)

A
  • asthma and COPD
  • metaproterenol, albuterol, salmeterol, isoetharine inhalers
  • bronchodilation w/o systemic effects
  • overdosing = B1 effects
37
Q

terbutaline and ritodrine

A

B2 agonists

  • used for tocolysis in pregnancy
  • B2 mediated relaxation of uterine smooth muscle
38
Q

INDIRECT acting sympathomimetics

A
  • cause the release of “stored” NE in the synaptic vesicles
  • BEWARE pts taking TCAs (NE reuptake inhibition) and MAOIs (NE breakdown inhibition)
39
Q

Ephedrine chemical structure

A
  • chemically an alkaloid w phenethylamine skeleton
40
Q

Ephedrine

A
  • indirect and direct actions on A and B receptors
  • competes w NE for reuptake in vesicles so NE stays at receptor sites longer
  • increased HR, BP, CO
  • tachyphylaxis
  • may increase MAC 2/2 stimulatory effects on CNS
41
Q

tachyphylaxis

A

rapidly diminishing response to successive doses of a drug, rendering it ineffective due to diminished stores and no reuptake

42
Q

amphetamine and METHamphetamine

A
  • indirect acting simpathomimetics
  • CNS stimulants, A and B receptor stimulants
  • cause release of an inhibit reuptake of stimulating neurotransmitters
  • effects related to A and B stimulation like other SNS stimulants
  • treatment of OD may include dantrolene to decrease temp
43
Q

methylphenidate

A
  • indirect acting sympathomimetic
  • ritalin
  • similar effects to amphetamine/meth but milder
  • txs ADHD
44
Q

Table 13-1 Relative Adrenergic Drug Effects on Peripheral Resistance and Capacitance Vessels

A
45
Q

Arginine Vasopressin

A
  • NOT a catechalamine!
  • endogenous hormone that regulaes urine volume and plasma osmolality
  • higher concentrations act on V1a receptors in VSM to vasoconstrict (via phosphoinositol pathway
46
Q

Arginine Vasopressin Dosage

A
  • 40 unit bolus instead of EPI 1mg in a code
  • used intraoperatively in 1-8 unit doses to tx refractory hypotension, ACE/ARB induced hypotension
  • 1-2 units at a dose is real nice
47
Q

phenoxybenzamine

A
  • adrenergic blocker
  • act post-synaptically competitively blocking A and B receptors
  • phenoxybenzamine and phetolamine block A receptors and vascular dilation occurs
  • phenoxybenzamine 1st choice to produce A blockade in pheochromocytoma patients
  • irreversible, non-competitive blocker T1/2 18-24 hours
  • dose: 10-20 mg PO BID for pheo
  • also txs neurogenic bladder and BPH
48
Q

Adrenergic Blockers:

B-Blockers

A
  • b-blockers target cardiac and vascular smooth muscle
  • B1 and B2 blockade (propranolol, labetalol)
  • B1 specific (atenolol, metoprolol, esmolol)
  • different drugs = different results
49
Q

reserpine and a-methyldopa and guanethidine

A
  • adrenergic blockers
  • reserpine and a-methyldopa block synthesis and storeage of NE
  • guanethidine blocks release of NE
50
Q

phentolamine

A
  • A-adrenergic blocker

used for infiltration when NE infusion infiltrates

51
Q

prazosin

A
  • A-Adrenergic blocker

high affinity for a receptors and txs HTN. PO at bedime

52
Q

doxazosin and tamulosin

A

a-adrenergic blocker

tx BPH

53
Q

B2 Blockade

A

B2 blockade =

  • bronchospasm and probs w PVD
  • bradycardia, asystole, HF, inhibits gluconeogenesis, raynaud’s
  • can cause severe HTN in pheo pts if they are given a dose prior to instituting an A blockade
  • Good: can reduce surgical M and M in pts w CAD
54
Q

Holding B Blockers prior to surgery?

A
  • may lead to rebound HTN that can last up to 6 days post-op
55
Q

Esmolol

A
  • selective B1 blocker
  • 90second onset, t1/2 9-10 mi
  • nonspecific red cell esterase metabolism (NOT metabolized by p-cholinesterase)
  • Dose: 10-20-40 mg boluses to reduce HTN
  • fast BP control desired w short duration
56
Q

Labetalol

A
  • A1, B1, and B2 blockade
  • a:b ratio 1:7
  • peripheral vasodilation w reflex tachycardia
  • peaks 5-15 min; duration 4-6 hours
  • Dose: 5-10 mg boluses q 5-10 min; wait for effect
  • continued BP control desired and tire of giving repeat doses of esmolol
57
Q

Metoprolol

A
  • primarily B1.
  • B1:B2 30:1 ratio
  • Dose: 2-5 mg q 2-5 min for total dose of 15mg
  • max B-blockade seen at 0.2 mg/kg
  • typically given to control HR when BP reduction not needed/desired
58
Q

Cholinergic Receptors:

Activation of postjunctional muscarinic receptors by Ach

A

Activation of postjunctional muscarinic receptors by Ach:

  • in the heart leads to bradycardia
  • in smooth muscle leads to bronchoconstriction, miosis, and increased GI motility/secretion
59
Q

Cholinergic Receptors:

Activation of presynaptic muscarinic receptors by Ach

A

at the presynaptic SNS terminals in the CV and coronaries leads to decreased NE release

60
Q

Cholinergic Receptors:

Nicotinic Receptors

A
  • nicotinic receptors activate postganglionic junctions in both SNS and PNS
  • NMJ nicotinic receptors are bloced by SUX which is an agonist at these sites
61
Q

Muscarinic Blockers

A
  • anticholinergic drugs (atropine, scopolamine, glycopyrolate) competitively inhibit Ach by reversibly binding to muscarinic receptors
  • atropine and scope = tertiary amine = cross BBB = CNS effects
  • may augment vagal outflow and cause brady at low doses (<0.5 mg)
  • glyco = quat amine = NOT cross BBB = NO CNS effects
  • more potent and longer acting at peripheral muscarinic receptors than atropine
62
Q

Cholinesterase Inhibitors

A
  • AChE inhibitors act indirectly resulting in an increase in Ach at ALL RECEPTOR SITES
  • directly inhibits action of both TRUE or acetylcholinesterase or PSEUDO or plasma cholinesterase
  • AChE found post-synaptically so AChE inhibiors act post-synaptically
63
Q

Cholinesterase Inhibitors:

NMDR Reversal Agents + eye drops

A

Neostigmine, Pyridostigmine, Physostigmine, Edrophonium (all NDMR reversal agents) and Echothiophate (eye drops)

  • desired effects at NMJ are at nicotinic receptors on NMJ
  • unwanted SE occur at muscarinic receptors so we administer a muscarinic blocking agent at the same time!
64
Q

SNS Receptors

A

A1, A2

B1, B2

D1, D2

65
Q

PSNS Receptors

A

Muscarinic - M 1,2,3,4

Nicotinic - N 1,2

Anesthesia Pharm Exam 2 (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions